At a glance
What is it—and why does it matter?
Octreotide is a cyclic peptide made of eight amino acids with long-acting somatostatin-like pharmacologic activity. Octreotide is reported as a full agonist at the human somatostatin SST5 receptor, with binding affinity expressed as pKi 7.2 - 9.5. In a two-case neonatal report of mutation-associated hypoglycemia (KCNJ11/ABCC8; congenital hyperinsulinism), octreotide administration was associated with stabilization of glycemic levels, after failure of enteral/parenteral glucose infusions and lack of clinical response to diazoxide. The labeled contraindication is allergy/hypersensitivity to the active peptide (octreotide) or excipients in MYCAPSSA, reflecting risk of serious allergic reactions.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Indication and transition instructions depend heavily on immediate-release, depot, or oral formulation. [1]Regulatory labelSandostatin prescribing informationCurrent DailyMed immediate-release octreotide label.
Identity + structure
A molecule, not a product name.
| Preferred name | Octreotide | Ingredient |
|---|---|---|
| Pharmacologic class | Somatostatin analog | Profile record |
| Peptide structure | 8 amino acids | Profile record |
| Also indexed as | octreotide · octreotide acetate · somatostatin analog | Search aliases |
Mechanism + clinical pharmacology
Target, response, and disposition.
Suppresses growth hormone and multiple gastrointestinal/pancreatic hormones through somatostatin receptors. [1]Regulatory labelSandostatin prescribing informationCurrent DailyMed immediate-release octreotide label.
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
CHEMBL1680 bound the human SST2 receptor with Ki = 0.4 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When PRRT eligibility was defined by NETTER-1 (Krenning ≥2), more patients met eligibility on PET than on planar imaging performed with [111In]octreotide scintigraphy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The reported overall incidence of delayed bleeding in the cohort was 20% (21 events among 107).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The 18 F-octreotide PET/CT demonstrated concordant high tracer uptake in lesions that corresponded to lesions with intense uptake on 18 F-FDG PET/CT in this case.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review analyzed 33 children with an average age of 6.3 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a retrospective multi-center chart review, post-initiation hypoglycemia frequency differed by octreotide route: IV infusion had a higher median count than IV bolus or subcutaneous administration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the analyzed group (n=28), octreotide scintigraphy was positive in 71.4% and negative in 28.6%, and all positive scans were graded as mild uptake.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The evidence summarized does not support a consensus recommendation for when to initiate octreotide in adult chylothorax.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
During active-drug treatment with octreotide, urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion was reduced.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In acromegaly, octreotide is reported to substantially reduce circulating growth hormone and/or insulin-like growth factor 1 (somatomedin C).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Treatment response in the analyzed cohort (n=28) was 67.9% responders and 32.1% non-responders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Symptom frequency (flushing and diarrhoea episodes) was prospectively recorded during a 1-week baseline and across the 8-week study period.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract characterizes the combination regimen (midodrine with octreotide) as commonly used in HRS-AKI when first-line or other vasoconstrictors are unavailable or impractical.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In acromegaly, octreotide is described as producing substantial biochemical reductions in growth hormone and/or insulin-like growth factor 1 (somatomedin C).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Postoperative octreotide scintigraphy (octreoscan) was used for systemic evaluation, but it failed to localize a primary NET in this patient.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In patients with acromegaly, octreotide produces marked suppression of growth hormone and/or insulin-like growth factor 1 (somatomedin C), with normalization in many cases.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This entry reports in vitro binding affinity (Ki) for SST4; it does not specify functional activity at the receptor.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an EBV-negative patient-derived xenograft (PDX-Li41) model, treatment with octreotide produced a statistically significant inhibition of xenograft growth.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is described as producing substantial suppression of GH and/or IGF-1 (somatomedin C) in acromegaly, with normalization in many cases.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The evidence base summarized in the abstract comprises three non-randomized observational studies evaluating clinical outcomes after octreotide use.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is indicated to lower GH and IGF-1 levels in some people with acromegaly when surgery, pituitary irradiation, and bromocriptine have not worked or cannot be used.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For patients treated with PRRT after inoperable progression following hepatic cytoreductive operation, the median overall survival reported was 97 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a two-patient case series of functioning GEP-NETs (gastrinoma and VIPoma) where CE-CT was non-diagnostic, [18F]F-NOTA-octreotide PET/CT provided anatomical localization of the primary lesions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When stratified by treatment response, the proportion with positive octreotide scintigraphy was 68.4% among responders and 77.8% among non-responders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Post-octreotide dextrose requirements differed by octreotide route in this retrospective review, with higher dextrose administered in the infusion group than in bolus or subcutaneous groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a humanized mouse model (immunocompromised mice engrafted with human KCNJ11-/- SC-islets), the combination of relamorelin with octreotide is reported to act synergistically on blood glucose and to reduce excessive insulin secretion.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the intention-to-treat analysis, CAM2029 increased the rate of biochemical control defined by IGF-1 ≤ULN at week 22/24 compared with placebo, with a reported risk difference and confidence interval.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In acromegaly, octreotide (BYNFEZIA PEN) is indicated for biochemical control by reducing circulating GH and IGF-1 when standard definitive therapies (surgery/irradiation) and bromocriptine at maximally tolerated doses are inadequate or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The abstract describes a possible longitudinal trajectory in HI: early hyperinsulinism can be followed by impaired fasting glucose/impaired glucose tolerance and later diabetes mellitus in some individuals.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract reports the sample size in terms of scans and patients and gives the cohort median age.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When PRRT eligibility was defined by NETTER-2 (Krenning ≥3), PET classified more patients as eligible than planar imaging performed with [111In]octreotide scintigraphy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this randomized comparison, stool frequency control did not meaningfully differ between subcutaneous octreotide and LAR octreotide dosing groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across EBV-positive and EBV-negative patient-derived xenograft models, the OCT-MMAE peptide-drug conjugate is reported to significantly inhibit xenograft growth.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across study arms, flushing control differed by regimen: the 20-mg LAR and SC octreotide groups had the best control, while 10-mg LAR had the least effective control of flushing.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this real-world claims dataset, switching to OCT-LAR from LAN-ATG was associated with a 21.9% decrease in breakthrough medication claims after switching.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study concluded that octreotide scintigraphy positivity occurred relatively frequently in patients with metastatic castration-resistant prostate cancer.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study design and inclusion window were a retrospective single-center analysis including all referrals for SSTR PET/CT during March 2023 to January 2024.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort’s liver metastases assessment, [68Ga]Ga-DOTATATE PET/CT showed lower sensitivity than [68Ga]Ga-FAP2286 (62% vs 82%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study defined elevated 5-HIAA as values exceeding 45 mumol 24 h-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this analysis, octreotide scan positivity did not show a statistically significant association with treatment response, with a reported P value of 1.00.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Co-administration with a permeation enhancer increased systemic exposure to octreotide in rats, as indicated by increased area under the plasma concentration–time curve (AUC), for both liquid and mini-tablet dosage forms.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The pharmacologic effect in acromegaly includes substantial reduction of circulating growth hormone and/or IGF-I (somatomedin C).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this claims-based cohort, switching from OCT-LAR to LAN-ATG was associated with a 66.5% reduction in breakthrough medication claims after the switch.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this adult-onset primary intestinal lymphangiectasia case, octreotide treatment initiation temporally coincided with gradual ascites resolution, consistent with a symptomatic improvement observed in a single patient.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CHEMBL1680 inhibited human SSTR5 with an IC50 of 22.0 nM in a radioligand binding assay.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Sandostatin Injection is used to lower GH and IGF-1 levels in some people with acromegaly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In CHO-K1 cells expressing human SSTR2, CHEMBL1680 inhibited forskolin-induced cAMP with EC50 = 0.03 nM (measured after 30 mins).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For carcinoid syndrome and VIPomas, the labeling states that effects on tumor burden and progression outcomes have not been determined for either immediate-release injection or long-acting suspension formulations.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a database review of patients treated with PRRT after inoperable progression following HCO, the reported median progression-free survival after PRRT was 32 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this spinal PMT case, the 18F-AlF-NOTA-octreotide PET/CT scan exhibited strong radiotracer uptake localized to the tumor lesion.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a two-case neonatal report of mutation-associated hypoglycemia (KCNJ11/ABCC8; congenital hyperinsulinism), octreotide administration was associated with stabilization of glycemic levels, after failure of enteral/parenteral glucose infusions and lack of clinical response to diazoxide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the EBV-positive patient-derived xenograft model PDX-B13, octreotide treatment is reported to have no tumor-growth-suppressive effect.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is used to lower GH and IGF-1 in some people with acromegaly when surgery/irradiation/bromocriptine are not adequate or not possible.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
In this reported case, disease progression occurred after initial treatment with octreotide, prompting a switch to chemotherapy (carboplatin plus etoposide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For these octreotide analogs, combining positive charge at residue 5 with higher lipophilicity (logD) is associated with greater sensitivity to phospholipid concentration in bile acid–phospholipid mixed micelles and increased micelle interaction.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is indicated to treat profuse watery diarrhea due to VIPoma-secreting tumors.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Hospital length of stay, reported as medians, varied across octreotide administration routes in this retrospective review.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The chart review evaluated treatment intensity and resource-use endpoints as secondary outcomes: octreotide dose, dextrose administration timing around the first dose, and length of stay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Outcome selection focused on post-octreotide hypoglycemia recurrence, measured as counts of hypoglycemic events after initiation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Tumor-to-background ratio in liver (TBRliver) favored [68Ga]Ga-FAP2286 over [68Ga]Ga-DOTATATE in this dual-tracer PET/CT comparison.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study’s conclusion was that octreotide scintigraphy positivity did not show a statistically significant association with response to 177Lu-prostate-specific membrane antigen radioligand therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Group sizes in the retrospective comparison were uneven, with the infusion group notably smaller than bolus or subcutaneous groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
The study design included randomization, double-blinding for the LAR arms (10, 20, 30 mg every 4 weeks), and an open-label comparator arm using SC octreotide every 8 hours in carcinoid syndrome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a blinded, placebo-controlled cross-over trial, octreotide treatment was associated with significantly fewer diarrhoea and flushing episodes than placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The randomized phase 3 study used high-dose long-acting repeatable octreotide (60 mg every 4 weeks) as the control regimen.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the human insulinoma-derived NT-3 cell line, certain dual SSTR2/SSTR5 agonists (SMTR-002/004/005) exceeded octreotide in insulin secretion inhibition at the specified concentration.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The comparator in this phase 3 trial was high-dose long-acting repeatable (LAR) octreotide administered at 60 mg every 4 weeks.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
When comparing imaging approaches, SSTR PET produced higher Krenning scores than planar imaging performed with [111In]octreotide scintigraphy, indicating stronger apparent somatostatin receptor signal on PET in this cohort.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the pre-switch period, OCT-LAR was associated with a higher percentage of patients exceeding the above maximum recommended dose (AMRD) threshold compared with LAN-ATG, with p value = 0.008.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The unadjusted DB proportions differed between groups: 24% (18/74) in the control group and 9% (3/33) in the octreotide group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanism
Source-backed statements about targets, pathways, and biological response.
Octreotide is reported as a full agonist at the human somatostatin SST3 receptor, with binding affinity expressed as pKi 7.4 - 8.6.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In PRRT, lutetium-177 is linked to octreotide as a radiolabeled peptide used to treat inoperable metastatic gastroenteropancreatic neuroendocrine tumors (GEPNETs).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acts like somatostatin and more strongly inhibits growth hormone, glucagon, and insulin than somatostatin does.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
18F-AlF-NOTA-octreotide (18F-OC) is described as a targeted probe with specific binding to somatostatin receptor–expressing tumors.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By suppressing pituitary TSH secretion, octreotide may reduce thyroid hormone signaling and lead to hypothyroidism.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral octreotide capsule (OOC) formulation is described as octreotide combined with transient permeability enhancer technology, implying a formulation approach to support oral delivery.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide in Sandostatin Injection produces somatostatin-like pharmacologic effects.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The in vitro methods described include a diffusion/transport proxy (flux through a porous cellulose dialysis membrane) and a stability assay against pancreatic enzymes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide scintigraphy positivity was used as a surrogate indicator for neuroendocrine differentiation, and the study assessed whether that imaging marker was associated with response to 177Lu-prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A cell-based FLIPR calcium assay using tetracycline-induced FLP-IN/T-REX 293 cells expressing an N-terminal Flag-tagged human MRGPRX2 receptor reported very low agonist potency for CHEMBL1680 (EC50 greater than 31622.78 nM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract attributes non-diagnostic conventional imaging to tumor factors—small lesion size and heterogeneity—leading to inconclusive or false-negative scans.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The biodistribution described for [¹⁸F]AlF-OC matches expected uptake in tissues that express somatostatin receptors (SSTR).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this report, FDG PET/CT is used to assess glucose metabolism while octreotide PET/CT is used to assess somatostatin receptor expression; the combined imaging is described as complementary for clinical evaluation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide served as a comparator SRL in preclinical neuroendocrine tumor cell-line assays, enabling relative assessment of novel SRLs.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to somatostatin, octreotide has greater inhibitory potency against growth hormone, glucagon, and insulin secretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Octreotide is reported as a full agonist at the human somatostatin SST2 receptor, with binding affinity expressed as pKi 8.7 - 9.9 (higher pKi indicates higher affinity).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
As a somatostatin analog, octreotide produces somatostatin-like pharmacology and increases inhibitory potency against growth hormone (GH), glucagon, and insulin secretion relative to native somatostatin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states octreotide suppresses pituitary TSH secretion, which can lead to hypothyroidism, supporting thyroid-function monitoring during chronic therapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate injection is a somatostatin analog with pharmacologic actions similar to endogenous somatostatin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A single-protein binding assay reported binding of CHEMBL1680 to the human SST4 receptor with Ki of 66.0 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used a semi-quantitative categorization of abnormal tracer uptake (mild/moderate/severe) using liver uptake as the reference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A cell-based functional assay (GloSensor cAMP) in CHO-K1 cells expressing human SSTR2 reported agonist potency for CHEMBL1680, producing inhibition of forskolin-stimulated cAMP with EC50 of 0.03 nM at a 30 mins measurement time.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Based on the described findings, the authors propose further development of a combination regimen pairing relamorelin with octreotide for severe KATPHI.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The experimental focus was on composition-dependent effects of BAPMM, specifically varying bile salt hydroxylation state and phospholipid concentration to assess peptide–micelle interactions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is reported as a full agonist at the human somatostatin SST5 receptor, with binding affinity expressed as pKi 7.2 - 9.5.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A single-protein binding assay reported high-affinity binding of CHEMBL1680 to the human SST2 receptor with Ki of 0.4 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
SSTR signaling functions as a potent inhibitory pathway for basal secretion of pancreatic islet hormones.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Radioligand binding data indicate low inhibitory potency of CHEMBL1680 at human SSTR4, with IC50 greater than 1000.0 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a single-protein radioligand binding assay, CHEMBL1680 showed inhibitory binding potency at human SSTR5 with an IC50 of 22.0 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
As a somatostatin analog, octreotide mimics somatostatin’s actions and is described as more potent at inhibiting secretion of growth hormone, glucagon, and insulin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using a regression approach, the source attributes flux-rate variation primarily to an interaction term between peptide lipophilicity (logD) and the charge at residue 5 (charge5).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate can reduce pituitary thyroid-stimulating hormone (TSH) secretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Octreotide has somatostatin-like pharmacodynamics, inhibiting secretion of anterior pituitary hormones (growth hormone and thyroid-stimulating hormone) and gastroenteropancreatic endocrine peptides.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This work evaluated whether an ex vivo viability readout in patient-derived 3D tumor cultures can serve as a proxy for intrinsic pharmacologic sensitivity and whether it corresponds to established clinical predictors.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
SSTR2 (somatostatin receptor 2) is reported as aberrantly upregulated in various tumors, and the source states that octreotide-based molecules can be used to therapeutically target SSTR2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide (Sandostatin) is a somatostatin analog with similar pharmacologic actions, reported to inhibit growth hormone, glucagon, and insulin more potently than somatostatin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
With repeated Sandostatin LAR dosing, steady-state pharmacokinetics were generally achieved by the second to third injection.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous administration results in rapid, complete absorption of octreotide from the injection site.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Following subcutaneous administration, the reported time to peak serum concentration for octreotide is within 30 minutes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The PK profile given indicates rapid absorption after SC administration, with a reported Cmax (5.2 ng/mL) and Tmax (0.4 hours) for a 100-mcg dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For a three minute intravenous infusion, octreotide reaches peak serum concentrations within four minutes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous administration results in rapid and complete absorption of octreotide from the injection site.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide is described as rapidly distributing with predominant plasma distribution and 65% plasma protein binding.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CAM2029 is formulated with FluidCrystal technology, which the source states increases the bioavailability of octreotide (more drug becomes available systemically).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide shows an apparent plasma elimination half-life in the range of 1.7 to 1.9 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
These pharmacokinetic values are reported for subcutaneous dosing and depend on the assay and study conditions; they do not directly predict clinical effect.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A cell-free assay measuring stability in human plasma reported a half-life (T1/2) of 1.5 hr for CHEMBL1680.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Following subcutaneous dosing, the source reports that about 32% of octreotide is recovered in urine as unchanged drug.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With the immediate-release formulation given subcutaneously, octreotide shows rapid absorption with reported Cmax 5.2 ng/mL after a 100-mcg dose at 0.4 hours (Tmax).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After a 100-mcg subcutaneous dose, peak blood levels were 5.2 ng/mL at 0.4 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
With immediate-release octreotide acetate injection given subcutaneously, systemic exposure peaks rapidly; for a 100 mcg dose, Cmax is 5.2 ng/mL at 0.4 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For immediate-release octreotide acetate injection, the text reports a peak concentration (Cmax) of 5.2 ng/mL after a 100-mcg subcutaneous dose, occurring at 0.4 hours (Tmax).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Double-blind single-dose clinical studies in acromegaly evaluated 10, 20, and 30 mg Sandostatin LAR to characterize its pharmacokinetic profile.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to endogenous somatostatin (minutes), octreotide has a longer apparent plasma elimination half-life (hours).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
The source states a mechanistic safety concern: octreotide may reduce gallbladder motility and bile secretion, predisposing to biliary abnormalities (e.g., sludge).
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
By decreasing gallbladder motility and bile secretion, octreotide depot therapy may predispose to biliary sludge or other gallbladder abnormalities.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Clinical-trial safety data in mainly acromegaly/psoriasis populations reported frequent biliary tract abnormalities during chronic octreotide acetate injection therapy, with specific proportions for gallstones, sludge, and biliary duct dilatation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity assessment in an open-label study found no detectable anti-octreotide antibodies (per the assay used) among 149 assessed patients during 13 months of MYCAPSSA treatment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
An overdosage statement reports specific adverse effects (hypoglycemia, flushing, dizziness, nausea) associated with 2.5 mg (2,500 mcg) subcutaneous octreotide acetate injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By altering counter-regulatory hormones (including insulin and glucagon), octreotide therapy may produce hypoglycemia or hyperglycemia; the label provides frequencies in acromegaly patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Clinical trials cited in labeling report a high incidence of biliary tract abnormalities during Sandostatin Injection therapy, with specific proportions for gallstones, sludge without stones, and biliary duct dilatation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A stated adverse physiology mechanism is reduced gallbladder contractility and bile secretion, which can predispose to gallbladder abnormalities or sludge.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In acromegaly populations treated with octreotide acetate injection or the long-acting injectable suspension, reported glucose disturbances included hypoglycemia (~2%) and hyperglycemia (~15%).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Clinical trial safety data for MYCAPSSA include reported glucose-related adverse reactions: hyperglycemia/increased blood glucose, hypoglycemia, and diabetes mellitus, with stated percentages.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The warning section quantifies biliary tract abnormalities seen in trials (primarily in acromegaly or psoriasis) during octreotide acetate therapy, including gallstones, sludge, and duct dilatation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide therapy (MYCAPSSA) can change endocrine counter-regulation involving insulin, glucagon, and GH, predisposing to dysglycemia including hypoglycemia, hyperglycemia, and diabetes mellitus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
TSH suppression is described as a pharmacodynamic effect of octreotide, with possible clinical consequence of hypothyroidism.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Cardiac-related adverse reactions reported in MYCAPSSA trials include bradycardia, conduction abnormalities, and arrhythmias/tachycardia with stated incidence percentages.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By altering counter-regulatory hormones (insulin, glucagon, and growth hormone), octreotide may dysregulate glycemia, leading to hypoglycemia or hyperglycemia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide (Sandostatin Injection) is reported to inhibit gallbladder contractility and decrease bile secretion, which may contribute to biliary abnormalities such as sludge.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity testing in an open-label MYCAPSSA study found no detectable anti-octreotide peptide antibodies among 149 assessed patients over 13 months.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
MYCAPSSA clinical trial safety reporting includes thyroid-related adverse reactions (hypothyroidism, increased thyroid-stimulating hormone, and decreased free thyroxine), each at 1%.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
The contraindication is hypersensitivity to octreotide acetate or excipients/components of the product.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not take MYCAPSSA if you are hypersensitive to octreotide or its ingredients; severe allergic reactions (including anaphylactic shock) have been reported with octreotide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled contraindication is hypersensitivity to Sandostatin Injection or its components.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindication: prior hypersensitivity to the active peptide (octreotide) or excipients precludes use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled contraindication for MYCAPSSA is hypersensitivity to the active peptide (octreotide) or excipients in the product.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The contraindication is stated as hypersensitivity; the section also notes reported anaphylactoid reactions with octreotide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled contraindication is allergy/hypersensitivity to the active peptide (octreotide) or excipients in MYCAPSSA, reflecting risk of serious allergic reactions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled contraindication is hypersensitivity to octreotide or formulation components; severe immediate hypersensitivity reactions have been reported with octreotide exposure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states SANDOSTATIN LAR DEPOT must not be administered by IV or subcutaneous routes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Interactions
Source-backed product and drug interaction statements.
A drug–drug interaction finding reported is reduced oral bioavailability of MYCAPSSA when co-administered with the proton pump inhibitor esomeprazole, consistent with pH-dependent absorption effects.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Competitive binding at somatostatin receptors is stated as the mechanism for potential reduction in lutetium Lu 177 dotatate efficacy when used with octreotide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A drug–drug interaction is described in which octreotide injection can decrease cyclosporine blood concentrations, with potential clinical consequence of transplant rejection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A potential drug interaction is reduced cyclosporine exposure when co-administered with octreotide acetate injection, with possible clinical consequence of transplant rejection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In Total Parenteral Nutrition (TPN) solutions, octreotide acetate injection is incompatible due to formation of a glycosylated octreotide conjugate, which may lower product efficacy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
This labeled indication is for diarrhea control in VIPoma-secreting tumors; it does not claim tumor reduction.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication for oral octreotide (MYCAPSSA) is long-term maintenance therapy in acromegaly, specifically for patients already shown to respond to and tolerate prior somatostatin analog therapy (octreotide or lanreotide).
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
The labeled indication includes treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) secretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For vasoactive intestinal peptide–secreting tumors (VIPomas), octreotide acetate injection is indicated to treat the associated profuse watery diarrhea.
8 cited sources · 8 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
10 cited passages across 8 source records.
This indication is conditional on prior response and tolerability to Sandostatin Injection; it does not specify a disease by itself in this sentence.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For carcinoid syndrome and VIPomas, it is not known whether octreotide affects tumor size, growth rate, or metastases.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication for the long-acting injectable suspension specifies use in patients with demonstrated effectiveness and tolerability on initial octreotide acetate injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
MYCAPSSA is used as long-term maintenance treatment for acromegaly in people who responded to and tolerated octreotide or lanreotide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes acromegaly requiring biochemical reduction of GH and IGF‑I when standard interventions (resection, irradiation, bromocriptine) are ineffective or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For acromegaly, octreotide acetate for injectable suspension is indicated for long-term maintenance in patients with inadequate response to surgery and/or radiotherapy or when those options are unsuitable.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
MYCAPSSA is used as long-term maintenance treatment for acromegaly in patients who responded to and tolerated octreotide or lanreotide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This section states intended use and a treatment goal (biochemical targets) but does not quantify expected response for any specific regimen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For acromegaly, octreotide acetate long-acting injectable suspension is indicated as long-term maintenance when surgery and/or radiotherapy is inadequate or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For carcinoid syndrome and VIPoma indications, the labeling states that antitumor outcomes (tumor size, growth kinetics, metastasis development) have not been determined for octreotide acetate injection or the injectable suspension.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
This indication is limited to patients whose initial treatment with octreotide acetate injection was effective and tolerated; it does not state benefit in injection-naïve patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states that antitumor effects (tumor size, growth rate, metastasis development) have not been determined for octreotide acetate injection or the long-acting injectable suspension in carcinoid syndrome and VIPomas.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
For acromegaly, Sandostatin Injection is indicated to reduce circulating GH and IGF-1 when standard interventions (surgical resection, pituitary irradiation, maximally tolerated bromocriptine) are inadequate or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes biochemical reduction of GH and IGF-1 in acromegaly when surgical resection, pituitary irradiation, and maximally tolerated bromocriptine mesylate are not effective or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For VIPomas (VIP-secreting tumors), octreotide acetate for injectable suspension is indicated for long-term treatment of profuse watery diarrhea.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 2 source records.
For acromegaly, SANDOSTATIN LAR DEPOT is labeled for long-term maintenance when definitive local therapies (surgery/radiotherapy) fail or cannot be used.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes management of VIPoma-associated secretory diarrhea.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes biochemical reduction of GH and IGF-1 in acromegaly patients who have not responded adequately to, or cannot receive, surgery, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For metastatic carcinoid tumors, octreotide acetate injection is an indicated symptomatic treatment for severe diarrhea and flushing episodes.
8 cited sources · 8 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
11 cited passages across 8 source records.
For VIP-secreting tumors, octreotide acetate injection is indicated to treat the associated profuse watery diarrhea.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled limitation notes that antitumor outcomes (tumor size, growth rate, metastases) have not been determined for octreotide (immediate-release or LAR) in carcinoid syndrome and VIPomas.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes biochemical reduction of growth hormone (GH) and insulin-like growth factor-1 (IGF-1; somatomedin C) in acromegaly when standard interventions (resection, irradiation, bromocriptine at maximally tolerated doses) are insufficient or not feasible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For VIPoma-associated secretory diarrhea, Sandostatin Injection is indicated to treat profuse watery diarrhea.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) secretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For metastatic carcinoid tumors, octreotide acetate for injectable suspension is indicated for long-term management of severe diarrhea and flushing episodes.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 2 source records.
Octreotide injection is indicated to lower GH and IGF‑I in acromegaly when surgery, pituitary irradiation, and maximally tolerated bromocriptine are inadequate or not possible.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication for the long-acting injectable suspension requires prior demonstration that immediate-release octreotide acetate injection was effective and tolerated.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 2 source records.
This indication specifies use of the long-acting depot formulation only after effectiveness and tolerability are demonstrated with Sandostatin Injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled use includes maintenance therapy for acromegaly in patients with inadequate response to, or inability to undergo, surgery and/or radiotherapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states that tumor-related outcomes (size, growth rate, metastasis development) have not been determined for these conditions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
MYCAPSSA (oral octreotide) has an approved indication for maintenance therapy in acromegaly after prior response and tolerability to somatostatin analog therapy (octreotide or lanreotide).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This statement describes the indicated acromegaly use context (post-surgery/radiotherapy inadequate response or not feasible) but does not provide response rates here.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
IV administration options include dilution (50–200 mL) for infusion over 15–30 minutes, or IV push administration over 3 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The labeled routes of administration for Sandostatin Injection include subcutaneous injection and intravenous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The labeled subcutaneous injection sites for BYNFEZIA PEN include abdomen, anterior mid-thigh, and posterior/lateral upper arm, supporting site selection for routine administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Initial SC dosing in acromegaly begins at 50 mcg three times daily, with subsequent titration based on biochemical markers.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration instructions specify oral dosing under fasting conditions to support absorption, and the delayed-release capsule should remain intact (no crushing/chewing) to preserve its release characteristics.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 1 source record.
The dosing instructions specify two parenteral routes (SC or IV), with SC described as the usual route when using octreotide acetate for symptom control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration instructions specify fasting administration with water and intact swallowing to preserve the delayed-release capsule performance.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate for injectable suspension is given as a gluteal IM injection every 4 weeks and should not be given IV or under the skin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The depot formulation is administered IM (gluteal) on a 4-week schedule; IV and subcutaneous routes are contraindicated for administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The long-acting injectable suspension formulation is administered via intramuscular injection into the gluteal region on a 4-week dosing interval.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product’s dosage forms/strengths are single-dose vials containing octreotide acetate injection at concentrations of 100 mcg per mL and 500 mcg per mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled route/site and schedule for SANDOSTATIN LAR DEPOT is intramuscular (gluteal) administration at 4-week intervals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial carcinoid syndrome dosing is subcutaneous, divided 2–4 times daily, totaling 100–600 mcg/day for the first 2 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product labeling permits parenteral administration by either subcutaneous (SC) injection or intravenous (IV) administration.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The product is labeled for intramuscular administration in the gluteal region on a 4-week dosing interval, with explicit instructions to avoid intravenous or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
The labeling recommends initiating octreotide acetate for acromegaly at 50 mcg subcutaneously three times daily before titration based on GH or IGF-1.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial carcinoid dosing guidance specifies 100–600 mcg/day SC, split into 2–4 doses, for the first 2 weeks (mean 300 mcg/day).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended starting regimen for oral octreotide (MYCAPSSA) is 40 mg/day split into 20 mg BID dosing.
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Initial carcinoid-tumor dosing guidance recommends 100–600 mcg/day of octreotide acetate injection subcutaneously, split into 2–4 doses, during the first 2 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If a patient has established liver cirrhosis, start octreotide acetate for injectable suspension at 10 mg every 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For carcinoid tumors (first 2 weeks), the dose is 100 to 600 mcg/day under the skin in 2 to 4 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For cirrhotic patients, labeling recommends a reduced starting dose regimen of 10 mg every 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial carcinoid dosing guidance specifies 100–600 mcg/day given subcutaneously in 2–4 divided doses for the first 2 weeks (mean 300 mcg/day).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This section provides a specific starting dose for ESRD; subsequent titration is based on IGF-1, signs/symptoms, and tolerability.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for VIPomas recommends subcutaneous octreotide acetate injection 200–300 mcg/day in 2–4 divided doses during the initial 2 weeks; a wider range of 150–750 mcg is noted for symptom control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In end-stage renal disease, start MYCAPSSA at 20 mg once daily by mouth.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage form is a prefilled pen delivering a clear, colorless octreotide acetate solution at 2,500 mcg/mL, totaling 7,000 mcg per 2.8 mL pen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For renal failure requiring dialysis, labeling recommends initiating octreotide acetate for injectable suspension at 10 mg once every 4 weeks.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Initial (first 2 weeks) dosing guidance for carcinoid tumors recommends subcutaneous octreotide acetate injection totaling 100–600 mcg/day in 2–4 divided doses; mean daily dose is 300 mcg.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
In acromegaly, octreotide acetate injection is initiated at 50 mcg SC three times daily before titration based on GH or IGF-1 levels.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The labeled initial dosing for dialysis-dependent renal failure is 10 mg of SANDOSTATIN LAR DEPOT administered every 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For metastatic carcinoid tumor symptoms, the first 2 weeks dose range is 100 to 600 mcg/day given subcutaneously in 2 to 4 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial titration in acromegaly begins with subcutaneous octreotide 50 mcg TID, with subsequent dose adjustments guided by biochemical monitoring elsewhere in the regimen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose ceiling: MYCAPSSA is not recommended above 80 mg/day per labeling.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For VIPomas (first 2 weeks), the recommended dose is 200 to 300 mcg/day under the skin in 2 to 4 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In acromegaly, the labeled initial regimen is 50 mcg subcutaneously three times daily.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
This section specifies a cirrhosis starting dose; subsequent titration guidance is not included in this section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial treatment dosing guidance for carcinoid tumors specifies a subcutaneous total daily dose range and divided dosing frequency over the first 2 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for acromegaly specifies subcutaneous octreotide acetate injection at 50 mcg three times daily.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
For acromegaly patients transitioning from immediate-release octreotide acetate injection, the label recommends initiating the long-acting suspension at 20 mg IM intragluteally every 4 weeks for 3 months before titration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This section states biochemical targets used to guide titration/monitoring; it does not provide evidence that these targets are always achieved.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If already on Sandostatin Injection for acromegaly, the label describes switching to Sandostatin LAR Depot 20 mg IM every 4 weeks for 3 months.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For acromegaly, the recommended starting dose is 50 mcg under the skin 3 times a day.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
For VIPomas, the initial 2 weeks recommend 200 to 300 mcg/day under the skin in 2 to 4 divided doses (range 150 to 750 mcg) to control symptoms.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial VIPoma dosing recommends SC dosing divided 2–4 times daily totaling 200–300 mcg/day (range 150–750 mcg) during the first 2 weeks for symptom control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose escalation for MYCAPSSA has an upper recommended limit of 80 mg per day; titration beyond this is not recommended per the dosing section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In acromegaly patients already on octreotide acetate injection, the recommended switch is 20 mg IM (intragluteal) every 4 weeks for 3 months.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For carcinoid tumors, during the first 2 weeks the recommended total daily dose is 100–600 mcg/day in 2–4 under-the-skin doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for acromegaly is 50 mcg administered subcutaneously three times per day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
For acromegaly, start BYNFEZIA PEN at 50 mcg under the skin 3 times daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Labeling specifies a lower starting dose of oral octreotide (MYCAPSSA) in ESRD, with subsequent individualized maintenance dosing guided by IGF-1 and clinical response/tolerability.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Titration is guided by biochemical control (IGF-1) and clinical status, using stepwise 20 mg/day increases.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial therapy for carcinoid tumors uses subcutaneous octreotide acetate injection at 100–600 mcg/day for the first 2 weeks, split into 2 to 4 doses.
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 5 source records.
The labeled capsule strength for oral delayed-release octreotide (MYCAPSSA) is 20 mg of octreotide content, supplied as the acetate salt.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In VIPoma-associated watery diarrhea, recommended initial dosing for symptom control over the first 2 weeks is 200–300 mcg/day subcutaneously in 2–4 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This statement applies to renal failure requiring dialysis; other renal impairment starting dose is addressed separately in the same section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For vasoactive intestinal peptide tumors (VIPomas), the recommended starting regimen over the initial 2 weeks is subcutaneous octreotide 200–300 mcg/day divided into 2 to 4 doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial VIPoma dosing recommendations specify 200–300 mcg/day SC divided into 2–4 doses for the initial 2 weeks (range 150–750 mcg) for symptom control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In acromegaly dosing, octreotide acetate is initiated at 50 mcg SC three times daily before titration based on GH/IGF-1.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For acromegaly dosing initiation, octreotide acetate injection is started at 50 mcg SC three times daily.
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 5 source records.
Studied populations
Who was represented in a study, label, or registry record.
Dose initiation in renal failure requiring dialysis is reduced: octreotide acetate long-acting suspension should start at 10 mg administered every 4 weeks.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This applies specifically to renal failure requiring dialysis and refers to starting dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal special population dosing: ESRD patients start at a lower initial oral dose (20 mg QD), with later adjustment based on response/tolerability.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This applies to established cirrhosis and addresses only the starting dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
The injection is supplied in sterile 1 mL ampuls with three labeled strengths: 50 mcg, 100 mcg, or 500 mcg octreotide (as acetate).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source characterizes congenital hyperinsulinism (HI) as genetically heterogeneous, with underlying disorders that disrupt regulation of insulin secretion.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is an acetate-salt, cyclic octapeptide drug product supplied as a sterile solution intended for parenteral administration (deep subcutaneous/intrafat or intravenous).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate injection is formulated as a cyclic octapeptide (octreotide acetate salt) intended for parenteral administration by deep subcutaneous or intravenous injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The case included germline genetic testing identifying a VHL p.Asp126Asn variant.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CAM2029 is an octreotide formulation designed as a subcutaneous depot (a long-acting injectable form placed under the skin).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The abstract states the creation of OCT-MMAE, a peptide-drug conjugate linking octreotide to monomethyl auristatin E.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is referenced as one of the long-acting somatostatin analogs considered in studies of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide Acetate Injection comes as a clear, single-dose vial: 50, 100, or 500 mcg per mL (as acetate).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The IUPHAR entry classifies [<sup>67</sup>Ga]NODAGA-[Tyr<sup>3</sup>]octreotide (Ligand ID 5628) as a peptide ligand.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is formulated as a cyclic octapeptide (octreotide, acetate salt) in a sterile solution designed for parenteral administration by deep subcutaneous or intravenous injection.
6 cited sources · 6 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 6 source records.
Octreotide acetate has a microencapsulated long-acting (LAR) formulation intended to enable monthly intramuscular administration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The dosage forms and strengths include clear-solution single-dose vials containing octreotide (as acetate) at concentrations of 100 mcg/mL or 500 mcg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate is a cyclic octapeptide (as an acetate salt) supplied as a sterile injectable solution intended for deep subcutaneous or intravenous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide is described as a water-soluble cyclic octapeptide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The dosage forms/strengths list octreotide (as acetate) injection as a clear solution in multi-dose vials at concentrations of 200 mcg/mL and 1000 mcg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate injection contains the peptide octreotide (as the acetate salt) formulated as a buffered acetic acid sterile solution for SC or IV administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In 68Ga-DOTATOC PET-CT, the imaging agent is octreotide (DOTA-D-Phe-Tyr-octreotide) labelled with gallium-68 to enable PET/CT detection.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is formulated as the acetate salt in a sterile solution and is intended for parenteral dosing by deep subcutaneous (intrafat) or intravenous injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide in Sandostatin Injection is a cyclic octapeptide provided as the acetate salt in a buffered lactic acid solution intended for deep subcutaneous or intravenous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate is categorized as a somatostatin receptor ligand used in acromegaly pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is categorized as a somatostatin analog and is listed among primary treatments for autosomal dominant polycystic kidney disease (ADPKD) or polycystic liver disease (PLD).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is identified here as a somatostatin analogue (a drug that mimics somatostatin signaling).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide subcutaneous (SC) depot is categorized as a somatostatin receptor ligand used in acromegaly pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is described as an 8-amino-acid cyclic peptide (a small cyclic peptide drug).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is a somatostatin analogue (a compound designed to mimic somatostatin’s actions).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within the study’s treatment taxonomy for malignant bowel obstruction, octreotide was specified as a medical management option.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
DOTATATE here is explicitly defined as [177Lu]Lu(lutetium)-(DOTA0, Tyr3) octreotide, i.e., an octreotide-based radioligand.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection comes as a clear, single-dose vial at 100 mcg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The active drug substance in MYCAPSSA is octreotide acetate, a somatostatin analog formulated as delayed-release oral capsules.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The molecular formula given for octreotide specifies its elemental composition as C49H66N10O10S2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The dosage form/strength specified is a clear single-dose vial solution containing octreotide (as acetate) at 100 mcg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide is a synthetic somatostatin analogue composed of 8 amino acids.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide was part of a set of additional cyclic peptides used for comparative validation of a graph-theoretic framework applied to cyclic peptide molecular graphs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Formulation/strength: MYCAPSSA is an oral delayed-release capsule delivering 20 mg of the peptide octreotide in the acetate salt form.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate in MYCAPSSA is classified as a somatostatin analog (a peptide drug that mimics somatostatin-like pharmacology).
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Oral octreotide is categorized as a somatostatin receptor ligand used in acromegaly pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is a cyclic octapeptide presented as an acetate salt, i.e., an 8-residue peptide with a cyclic structure formulated with acetate.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
The source notes ambiguity in stereochemical representation for octreotide; the displayed structure omits stereochemistry, which can lead to differences versus other chemical resources.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study administered a radiolabeled octreotide analogue, 177Lu-DOTA-TATE, as the PRRT compound.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide long-acting release (LAR) is categorized as a somatostatin receptor ligand used in acromegaly pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is a cyclic peptide made of eight amino acids with long-acting somatostatin-like pharmacologic activity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide acetate injection is a cyclic octapeptide solution given by deep subcutaneous or intravenous injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Octreotide acetate (a somatostatin analog) is described as a cyclic octapeptide provided as a sterile injectable solution (acetate salt).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Additional research & classification gaps
39 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (39)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In NT-3 3D spheroid cultures, SMTR-002’s antisecretory effect on insulin was reported as comparable to octreotide, indicating similar magnitude in that model.
Research context only—not evidence of a treatment effect.
- Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models.
In 3D cultures of NT-3 cells, SMTR-002 reduced insulin secretion to a degree comparable to octreotide but, unlike octreotide, significantly decreased cell proliferation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a nationwide survey assessing HRS-AKI management practices, respondents reported first-line vasoconstrictor regimen preferences; midodrine/octreotide was selected by 44% of providers, while terlipressin was selected by 49%.
Research context only—not evidence of a treatment effect.
- The management of hepatorenal syndrome-acute kidney injury (HRS-AKI): A national survey of hepatology provider practices.
Terlipressin (49%) and midodrine/octreotide (44%) were preferred first-line treatments
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across the peptide set, bile salt hydroxylation state matters: dihydroxy BAPMM produces stronger peptide–micelle interactions than trihydroxy BAPMM.
Research context only—not evidence of a treatment effect.
- The role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.
All peptides exhibit stronger interactions with dihydroxy-versus trihydroxy-containing BAPMM
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated objective was to evaluate an association between postprocedural octreotide exposure and delayed bleeding following duodenal EMR in large superficial non-ampullary duodenal tumors.
Research context only—not evidence of a treatment effect.
- Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors.
This exploratory study aimed to evaluate the association between postprocedural octreotide use and DB after duodenal EMR for large SNADTs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Co-infusion of octreotide attenuated amino-acid–stimulated islet hormone responses, leaving 49% of the glucagon response, 43% of the insulin response, and 78% of the C‑peptide response compared with amino acids alone.
Research context only—not evidence of a treatment effect.
- Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals.
When amino acids and octreotide were co‑infused, the amino acid-driven elevations in glucagon, insulin and C‑Peptide were reduced to 49%, 43% and 78% of the levels achieved by amino acids alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review defined its primary endpoint as resolution of crisis symptoms.
Research context only—not evidence of a treatment effect.
- Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Resolution of crisis symptoms was the primary outcome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When residue 5 carries a negative charge, the octreotide analogs show reduced sensitivity to phospholipid concentration changes in the BAPMM system.
Research context only—not evidence of a treatment effect.
- The role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.
Conversely, analogs with a negative charge5 are less influenced by changes in PL concentration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this report, combining 18 F-FDG PET/CT (glucose metabolism) with 18 F-octreotide PET/CT (somatostatin receptor expression) yielded complementary imaging information for VHL-mutated pheochromocytoma.
Research context only—not evidence of a treatment effect.
- pubmed-42029102
This "dual-tracer" strategy provided complementary information on glucose metabolism and somatostatin receptor expression, facilitating prognostic stratification and therapeutic decision-making in VHL-mutated pheochromocytoma.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Transcriptomic and protein analyses in the EBV-negative PDX-Li41 model found heterogeneous regulation of cell-cycle-related genes with pathway-level shifts: DNA replication pathways were upregulated, while cell-signaling and neurotransmitter-release pathways were downregulated after octreotide treatment.
Research context only—not evidence of a treatment effect.
- SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.
In the EBV-negative PDX-Li41 model, treatment with the SSTR2 agonist octreotide (OCT) significantly inhibited xenograft growth and showed additive effects with chemotherapy; transcriptomic and protein analyses revealed heterogeneous regulation of cell-cycle-related genes, upregulation of DNA replication pathways, downregulation of cell-signaling and neurotransmitter-release pathways,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Amino acids act as strong secretagogues for glucagon release.
Research context only—not evidence of a treatment effect.
- Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals.
Amino acids potently stimulate glucagon secretion and can stimulate insulin secretion, although less potently than glucose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In carcinoid syndrome, subcutaneous octreotide acetate is stated to effectively relieve two hallmark symptoms: diarrhea and flushing.
Research context only—not evidence of a treatment effect.
- Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a Caco-2 intestinal epithelial cell model, complexing octreotide with stearic acid-functionalised mesoporous silica increased measured trans-epithelial transport versus unformulated octreotide.
Research context only—not evidence of a treatment effect.
- Functionalised mesoporous silica with stearic acid: A novel approach to improve octreotide delivery.
Permeability studies using Caco-2 cells showed increased octreotide transport with the complex (2.68 ± 0.34%) compared to free octreotide (0.8 ± 0.16%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using immunohistochemistry in a retrospective set of lymphoma cases, the study reports SSTR2 positivity in 43% (20/47) of EBV-positive classic Hodgkin lymphoma and none (0/12) of EBV-negative classic Hodgkin lymphoma.
Research context only—not evidence of a treatment effect.
- SSTR2 expression in EBV-positive and EBV-negative lymphomas.
We found SSTR2 expression in 43% (20/47) of EBV-positive classic Hodgkin lymphomas (cHL) and 0% (0/12) of EBV-negative cHL cases.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the Caco-2 permeability assay, adding the permeation enhancer SNAC to octreotide produced a measured transport value of 2.59 ± 0.38%.
Research context only—not evidence of a treatment effect.
- Functionalised mesoporous silica with stearic acid: A novel approach to improve octreotide delivery.
Transport with octreotide combined with permeation enhancers SNAC (2.59 ± 0.38%) or SNAC + TPGS (over 20%) was also measured
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the EBV-negative PDX-Li41 xenograft model, transcriptomic/protein analyses reported reduced expression of specific regulators (CDK6, NF-κB, E2F1, CDK2) and BIRC5 following octreotide treatment.
Research context only—not evidence of a treatment effect.
- SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.
and reduced expression of CDK6, NF-κB, E2F1, CDK2, and BIRC5.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among EBV-negative follicular lymphoma cases in this series, SSTR2 expression by immunohistochemistry is reported in 17% (5/29).
Research context only—not evidence of a treatment effect.
- SSTR2 expression in EBV-positive and EBV-negative lymphomas.
and 17% (5/29) of follicular lymphomas showed SSTR2 expression.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The octreotide–monomethyl auristatin E conjugate (OCT-MMAE) is reported to internalize into cells efficiently (no assay details provided in the abstract).
Research context only—not evidence of a treatment effect.
- SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.
which demonstrated efficient cellular internalization,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to glucose, amino acids are weaker stimuli for insulin secretion.
Research context only—not evidence of a treatment effect.
- Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals.
Amino acids potently stimulate glucagon secretion and can stimulate insulin secretion, although less potently than glucose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states that SC octreotide acetate is effective for relieving two key carcinoid syndrome symptoms: diarrhea and flushing.
Research context only—not evidence of a treatment effect.
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This source lists SMS995 as an alternate identifier/name for octreotide.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
Octreotida; Octreotide; SMS 201-995; SMS-201-995; SMS-995; SMS995
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
18F-AlF-NOTA-octreotide is described as a fluorinated ligand that targets somatostatin receptors for PET imaging.
Research context only—not evidence of a treatment effect.
- Update on PET Imaging of Neuroendocrine Neoplasms.
Emerging advances include fluorinated SSTR ligands (e.g.,18F-AlF-NOTA-octreotide,18F-SiTATE),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This source lists alternate names (synonyms) for octreotide, including Octreotida.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
Octreotida; Octreotide; SMS 201-995; SMS-201-995; SMS-995; SMS995
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide subcutaneous depot is called CAM2029.
Research context only—not evidence of a treatment effect.
- What is the future of acromegaly therapy?
Octreotide subcutaneous depot (CAM2029)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source lists SMS 201-995 as an alternate name used for octreotide.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
Octreotida; Octreotide; SMS 201-995; SMS-201-995; SMS-995; SMS995
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL lists OCTREOTIDE as the preferred name for this molecule entry.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
Preferred name: OCTREOTIDE
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is described as a somatostatin mimetic (a compound that mimics somatostatin’s actions).
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
Octreotide is a somatostatin mimetic.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This synonym list includes the hyphenated form SMS-201-995 for octreotide.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
Octreotida; Octreotide; SMS 201-995; SMS-201-995; SMS-995; SMS995
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide Long-Acting Release (OCT-LAR) is categorized as a long-acting somatostatin analog (SSA).
Research context only—not evidence of a treatment effect.
- Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.
Long-acting somatostatin analogs (SSA) such as Lanreotide Autogel® (LAN-ATG) and Octreotide Long-Acting Release (OCT-LAR)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ChEMBL, octreotide is indexed under the identifier CHEMBL1680.
Research context only—not evidence of a treatment effect.
- OCTREOTIDE
ChEMBL ID: CHEMBL1680
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Proteomics/western blotting characterization identified abundant transport-associated proteins (PIGR, MFGE8, ANXA2, CD9, CD63, CD81) in donkey-milk exosomes.
Research context only—not evidence of a treatment effect.
- Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.
abundant transport-associated proteins including PIGR, MFGE8, ANXA2, CD9, CD63, and CD81.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract characterizes Mycapssa® as relying on transient intestinal tight-junction disruption to enhance permeability.
Research context only—not evidence of a treatment effect.
- Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.
and reliance on the transient disruption of intestinal tight junctions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Physiologically, δ-cell–derived somatostatin acts as an inhibitor of pancreatic islet hormone secretion.
Research context only—not evidence of a treatment effect.
- Amino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals.
Endogenous somatostatin released from pancreatic δ-cells inhibits islet hormone output.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide is described as having pharmacological effects that may affect hemostasis, which could lower bleeding risk.
Research context only—not evidence of a treatment effect.
- Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors.
Octreotide exerts pharmacological effects that may influence hemostasis and thereby reduce bleeding risk.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract explicitly describes the octreotide-based PET approach as SSTR-targeted PET imaging (i.e., targeting somatostatin receptors).
Research context only—not evidence of a treatment effect.
- pubmed-42333429
This case emphasizes an important diagnostic trap, as benign fibromatosis can mimic NET metastasis on both anatomic and SSTR-targeted PET imaging, alerting clinicians to avoid misdiagnosis and unnecessary treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Octreotide exerts endocrine and hemodynamic actions, including suppression of growth hormone secretion and reduction of splanchnic blood flow.
Research context only—not evidence of a treatment effect.
- Debut of a somatostatin analog: octreotide in review.
It also suppresses growth hormone and decreases splanchnic blood flow.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Scanning electron microscopy (SEM) observations reported in the abstract indicate needle-like stearic acid features present on the mesoporous silica surface.
Research context only—not evidence of a treatment effect.
- Functionalised mesoporous silica with stearic acid: A novel approach to improve octreotide delivery.
SEM imaging highlighted the presence of stearic acid needles on the silica surface
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Characterization of exosomes isolated from donkey milk powder yielded a mean particle size of 138.4 ± 4.37 nm and a zeta potential of -42.07 ± 0.99 mV.
Research context only—not evidence of a treatment effect.
- Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.
found to possess a mean size of 138.4 ± 4.37 nm, and zeta potential of -42.07 ± 0.99 mV
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Radiochemical purity (RCP) for [18F]AlF-NOTA-Octreotide was reported as >95%, with stability maintained for 8 hours at room temperature, indicating the labeled octreotide tracer remained chemically intact over that period.
Research context only—not evidence of a treatment effect.
- Optimization of automated radiosynthesis method for [18F]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms.
The RCP was > 95% and remained stable for 8 hours at room temperature.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Following subcutaneous administration, octreotide shows complete and rapid absorption.
Research context only—not evidence of a treatment effect.
- Debut of a somatostatin analog: octreotide in review.
Octreotide is completely and rapidly absorbed following subcutaneous injection
Safety + tolerability
Risks, organized for scanning.
Contraindications
- Serious hypersensitivity; additional restrictions are product-specific
Common effects
- Gallbladder abnormalities
- Diarrhea
- Abdominal pain
- Nausea
- Injection-site pain
- Headache
Serious risks
- Cholelithiasis and complications
- Glucose dysregulation
- Bradycardia and conduction abnormalities
- Thyroid function changes
- Nutrient malabsorption
Structured from current product labeling [1]Regulatory labelSandostatin prescribing informationCurrent DailyMed immediate-release octreotide label.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| Sandostatin | Subcutaneous or intravenous injection | Selected acromegaly and severe secretory diarrhea syndromes. | [1]Regulatory labelSandostatin prescribing informationCurrent DailyMed immediate-release octreotide label. |
| Sandostatin LAR Depot | Long-acting intramuscular depot | Maintenance treatment in product-specific indications. | [22]Published evidence snapshotThese highlights do not include all the information needed to use SANDOSTATIN LAR DEPOT safely and effectively. See full prescribing information for SANDOSTATIN LAR DEPOT.SANDOSTATIN®LAR DEPOT (octreotide acetate) for injectable suspension, for gluteal intramuscular useInitial U.S. Approval: 1988dailymed · T1 |
| Mycapssa | Delayed-release oral capsule | Maintenance treatment in selected acromegaly patients. | [13]Published evidence snapshotThese highlights do not include all the information needed to use MYCAPSSA®safely and effectively. See full prescribing information for MYCAPSSA.MYCAPSSA (octreotide) delayed-release capsules, for oral useInitial U.S. Approval: 1988dailymed · T1 |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Subcutaneous, intravenous, intramuscular depot, or oral delayed-release depending on product. [1]Regulatory labelSandostatin prescribing informationCurrent DailyMed immediate-release octreotide label.
Research status + gaps
What still needs better answers.
1540 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (826), assurance_score_below_0.72 (590), current_regulatory_source_required (418), evidence_scope (342), extraction_ambiguity (915), extraction_confidence_not_high (2), high_risk_requires_regulatory_or_two_independent_sources (680), no_direct_support (1408), proposal_not_staged (30)
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelSandostatin prescribing informationOpen ↗
Current DailyMed immediate-release octreotide label.
- 2Literature indexEvery PubMed result for octreotideOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 3Trial registryEvery registered study for octreotideOpen ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.
- 4Chemical recordoctreotide chemical recordOpen ↗
PubChem compound search from the National Library of Medicine.
- 5Published evidence snapshotChEMBL activities for CHEMBL1680Open ↗
chembl-activities · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 6Published evidence snapshotOCTREOTIDEOpen ↗
chembl-molecule · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 7Published evidence snapshotHIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to useOCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-01-16 · retrieved 2026-08-24T17:38:00Z - 8Published evidence snapshotThese highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN.BYNFEZIA PEN®(octreotide acetate) injection, for subcutaneous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-02-21 · retrieved 2026-08-24T17:38:00Z - 9Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-07-25 · retrieved 2026-08-28T12:18:09Z - 10Published evidence snapshotThese highlights do not include all the information needed to useOCTREOTIDE ACETATE INJECTIONsafely and effectively. See full prescribing information forOCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-07-15 · retrieved 2026-08-24T17:38:00Z - 11Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2026-01-30 · retrieved 2026-08-21T17:03:42Z - 12Published evidence snapshotThese highlights do not include all the information needed to use SANDOSTATIN INJECTION safely and effectively. See full prescribing information for SANDOSTATIN INJECTION.SANDOSTATIN®(octreotide acetate) INJECTION, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2026-07-22 · retrieved 2026-08-18T22:04:15Z - 13Published evidence snapshotThese highlights do not include all the information needed to use MYCAPSSA®safely and effectively. See full prescribing information for MYCAPSSA.MYCAPSSA (octreotide) delayed-release capsules, for oral useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-07-24 · retrieved 2026-08-24T17:18:21Z - 14Published evidence snapshotOctreotide Acetate InjectionOpen ↗
dailymed · T1
Published 2012-10-10 · retrieved 2026-08-18T22:04:11Z - 15Published evidence snapshotThese highlights do not include all the information needed to use MYCAPSSA®safely and effectively. See full prescribing information for MYCAPSSA.MYCAPSSA (octreotide) delayed-release capsules, for oral useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-07-24 · retrieved 2026-08-18T22:04:04Z - 16Published evidence snapshotRx OnlyPrescribing InformationOpen ↗
dailymed · T1
Published 2018-09-21 · retrieved 2026-09-01T08:37:10Z - 17Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-07-01 · retrieved 2026-08-24T17:38:00Z - 18Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-07-29 · retrieved 2026-08-28T12:18:09Z - 19Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE injection, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-03-01 · retrieved 2026-08-24T17:18:21Z - 20Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE INJECTION, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-06-25 · retrieved 2026-08-24T17:18:21Z - 21Published evidence snapshotRx ONLYOpen ↗
dailymed · T1
Published 2019-01-07 · retrieved 2026-09-01T08:37:10Z - 22Published evidence snapshotThese highlights do not include all the information needed to use SANDOSTATIN LAR DEPOT safely and effectively. See full prescribing information for SANDOSTATIN LAR DEPOT.SANDOSTATIN®LAR DEPOT (octreotide acetate) for injectable suspension, for gluteal intramuscular useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2025-12-22 · retrieved 2026-08-18T22:04:06Z - 23Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE INJECTION, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-05-23 · retrieved 2026-08-28T12:18:09Z - 24Published evidence snapshotThese highlights do not include all the information needed to useOCTREOTIDE ACETATE FOR INJECTABLE SUSPENSIONsafely and effectively. See full prescribing information forOCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION.OCTREOTIDE ACETATEfor injectable suspension, for gluteal intramuscular useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-07-30 · retrieved 2026-08-18T22:04:08Z - 25Published evidence snapshotOctreotide Acetate InjectionOpen ↗
dailymed · T1
Published 2012-10-10 · retrieved 2026-09-01T08:37:10Z - 26Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION.OCTREOTIDE ACETATE for injectable suspension, for gluteal intramuscular useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2026-01-21 · retrieved 2026-08-21T17:03:42Z - 27Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE INJECTION, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-05-07 · retrieved 2026-08-25T11:03:05Z - 28Published evidence snapshotThese highlights do not include all the information needed to use OCTREOTIDE ACETATE INJECTION safely and effectively. See full prescribing information for OCTREOTIDE ACETATE INJECTION.OCTREOTIDE ACETATE INJECTION, for subcutaneous or intravenous useInitial U.S. Approval: 1988Open ↗
dailymed · T1
Published 2024-12-03 · retrieved 2026-08-28T12:18:09Z - 29Published evidence snapshotOctreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeOpen ↗
doi · T6
Published 1999-02-01 · retrieved 2026-09-09T18:01:34Z - 30Published evidence snapshotIUPHAR ligand commentaryOpen ↗
iuphar-comments · T6
Published 2026-08-24 · retrieved 2026-08-24T17:18:21Z - 31Published evidence snapshotIUPHAR interactions for octreotideOpen ↗
iuphar-interactions · T6
Published 2026-08-24 · retrieved 2026-08-24T17:18:21Z - 32Published evidence snapshot[<sup>67</sup>Ga]NODAGA-[Tyr<sup>3</sup>]octreotideOpen ↗
iuphar-ligand · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 33Published evidence snapshotOctreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.Open ↗
pubmed · T2
Published 1999-02-01 · retrieved 2026-09-09T18:01:33Z - 34Published evidence snapshotMega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.Open ↗
pubmed · T2
Published 2013-05-01 · retrieved 2026-09-09T22:30:04Z - 35Published evidence snapshotDebut of a somatostatin analog: octreotide in review.Open ↗
pubmed · T3
Published 1989-12-01 · retrieved 2026-09-09T22:30:03Z - 36Published evidence snapshotOctreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.Open ↗
pubmed · T3
Published 1989-11-01 · retrieved 2026-09-08T10:56:07Z - 37Published evidence snapshotOral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.Open ↗
pubmed · T3
Published 2022-06-01 · retrieved 2026-09-09T22:30:04Z - 38Published evidence snapshotOctreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.Open ↗
pubmed · T2
Published 2025-05-19 · retrieved 2026-09-08T21:45:41Z - 39Published evidence snapshotComprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap.Open ↗
pubmed · T3
Published 2026-04-25 · retrieved 2026-09-09T08:36:24Z - 40Published evidence snapshotFunctionalised mesoporous silica with stearic acid: A novel approach to improve octreotide delivery.Open ↗
pubmed · T3
Published 2026-04-25 · retrieved 2026-09-01T08:37:10Z - 41Published evidence snapshotAnti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T09:00:33Z - 42Published evidence snapshotDual-tracer PET/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET).Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-09-01T08:37:10Z - 43Published evidence snapshotReal-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-04T22:24:53Z - 44Published evidence snapshotSSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-09T08:36:24Z - 45Published evidence snapshotCongenital Hyperinsulinism in Neonates: Diagnostic Challenges and Management in Two Cases With KCNJ11 and ABCC8 Mutation.Open ↗
pubmed · T3
Published 2026-02-01 · retrieved 2026-09-09T08:36:24Z - 46Published evidence snapshot[Optimal timing for octreotide administration in adult patients with chylothorax: A scoping review].Open ↗
pubmed · T3
Published 2026-06-16 · retrieved 2026-08-24T17:38:00Z - 47Published evidence snapshotPulmonary neuroendocrine tumour-associated ectopic Cushing's syndrome: diagnostic challenges and multidisciplinary management.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:43:42Z - 48Published evidence snapshotEffect of octreotide-deoxycholate hydrophobic ion pairing solid dispersions on intestinal permeability to enhance octreotide absorption via increased lipophilicity and ASBT-mediated transport.Open ↗
pubmed · T3
Published 2026-05-05 · retrieved 2026-09-01T08:37:10Z - 49Published evidence snapshotMedical Versus Surgical/Endoscopic Management of Malignant Bowel Obstruction in Patients With End-Stage Gynecologic Cancer: A 12-Year Single-Center Experience.Open ↗
pubmed · T3
Published 2026-02-01 · retrieved 2026-09-09T08:36:24Z - 50Published evidence snapshotMidodrine Monotherapy in Refractory Hepatorenal Syndrome-Acute Kidney Injury: A Case Report.Open ↗
pubmed · T3
Published 2026-02-01 · retrieved 2026-09-09T08:36:24Z - 51Published evidence snapshotThe management of hepatorenal syndrome-acute kidney injury (HRS-AKI): A national survey of hepatology provider practices.Open ↗
pubmed · T3
Published 2026-04-01 · retrieved 2026-09-05T08:43:42Z - 52Published evidence snapshotPrimary Intestinal Lymphangiectasia Presenting as Recurrent Chylous Ascites: A Rare Case.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-09T08:36:24Z - 53Published evidence snapshotSSTR2 expression in EBV-positive and EBV-negative lymphomas.Open ↗
pubmed · T3
Published 2026-04-10 · retrieved 2026-09-05T08:43:42Z - 54Published evidence snapshotWhat is the future of acromegaly therapy?Open ↗
pubmed · T3
Published 2026-06-04 · retrieved 2026-08-24T17:38:00Z - 55Published evidence snapshotDevelopments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-08-28T12:18:09Z - 56Published evidence snapshotOctreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-09T08:36:24Z - 57Published evidence snapshotA 13-Year-Old Girl with Congenital Hyperinsulinemic Hypoglycemia Due to anABCC8Mutation and Recent Onset of Diabetes Mellitus: A Case Report and Literature Review.Open ↗
pubmed · T3
Published 2026-04-14 · retrieved 2026-09-05T08:43:42Z - 58Published evidence snapshotIdentification and Localization of Functioning Gastroenteropancreatic Neuroendocrine Tumors Using [18F]F-NOTA-octreotide PET/CT.Open ↗
pubmed · T3
Published 2026-03-31 · retrieved 2026-09-05T08:43:42Z - 59Published evidence snapshotOptimization of automated radiosynthesis method for [18F]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms.Open ↗
pubmed · T3
Published 2026-04-21 · retrieved 2026-09-01T08:37:10Z - 60Published evidence snapshotUptake of18F-AlF-NOTA-octreotide PET/CT in gastrointestinal stromal tumors.Open ↗
pubmed · T3
Published 2026-04-24 · retrieved 2026-09-01T08:37:10Z - 61Published evidence snapshotpubmed-42029102Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 62Published evidence snapshotUpdate on PET Imaging of Neuroendocrine Neoplasms.Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-09-05T08:43:42Z - 63Published evidence snapshotComparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.Open ↗
pubmed · T3
Published 2026-06-12 · retrieved 2026-08-24T17:38:00Z - 64Published evidence snapshotAmino acids partially override inhibitory effects of octreotide on islet hormone secretion in healthy individuals.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-24T17:18:21Z - 65Published evidence snapshotEvaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:43:42Z - 66Published evidence snapshotpubmed-42333429Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 67Published evidence snapshotSpinal phosphaturic mesenchymal tumor: a case report of thoracic vertebral involvement with preoperative embolization and literature review.Open ↗
pubmed · T3
Published 2026-07-03 · retrieved 2026-08-24T17:18:21Z - 68Published evidence snapshotpubmed-42442014Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 69Published evidence snapshotComparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database.Open ↗
pubmed · T3
Published 2026-07-20 · retrieved 2026-08-21T17:03:42Z - 70Published evidence snapshotEx Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors.Open ↗
pubmed · T3
Published 2026-07-24 · retrieved 2026-09-09T08:36:24Z - 71Published evidence snapshotImpact of dosage form on the pharmacokinetics of octreotide after oral administration with permeation enhancers.Open ↗
pubmed · T3
Published 2026-09-05 · retrieved 2026-09-05T08:43:42Z - 72Published evidence snapshotEfficacy and Safety of Octreotide for Gastrointestinal Bleeding Due to Portal Hypertension in Children-A Systematic Review.Open ↗
pubmed · T3
Published 2026-06-24 · retrieved 2026-08-24T17:18:21Z - 73Published evidence snapshotAnalysis of outcome in patients with different primary localisation of neuroendocrine tumors after PRRT. 10 years single institution experience.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-09T08:36:24Z - 74Published evidence snapshotGhrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.Open ↗
pubmed · T3
Published 2026-07-20 · retrieved 2026-08-21T17:03:42Z - 75Published evidence snapshotSolitary left frontotemporal neuroendocrine metastasis mimicking a high-grade astrocytoma.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-21T17:03:42Z - 76Published evidence snapshotMultiple skin and subcutaneous metastasis as initial manifestation in neuroendocrine carcinoma lung: A rare case report.Open ↗
pubmed · T3
Published 2026-10-01 · retrieved 2026-08-17T23:10:15Z - 77Published evidence snapshotStructural control and resilience in the oxytocin molecular graph: A graph-theoretic framework for critical atom and bond identification with comparative validation across cyclic peptides.Open ↗
pubmed · T3
Published 2026-11-01 · retrieved 2026-09-07T08:44:20Z - 78Published evidence snapshotEditorial: Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-09T08:36:24Z - 79Published evidence snapshotpubmed-42604001Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 80Published evidence snapshotThe role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.Open ↗
pubmed · T3
Published 2026-09-04 · retrieved 2026-09-05T08:43:42Z - 81Published evidence snapshotAssessment of Neuroendocrine Features Using 99mTc-Octreotide Scintigraphy in Patients with Metastatic Castration-Resistant Prostate Cancer: Does it Predict Response to 177Lu-PSMA Radioligand Therapy?Open ↗
pubmed · T3
Published 2026-08-29 · retrieved 2026-09-05T08:43:42Z - 82Published evidence snapshotOctreotide Administration Methods in Sulfonylurea Poisoning: A Retrospective Chart Review.Open ↗
pubmed · T3
Published 2026-09-02 · retrieved 2026-09-05T08:43:42Z - 83Published evidence snapshotDifferential Somatostatin Sensitivity of Corticotropic and Somatotropic Responses Following Amino Acid Infusion.Open ↗
pubmed · T3
Published 2026-09-04 · retrieved 2026-09-05T08:43:42Z - 84Published evidence snapshotClinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.Open ↗
pubmed · T2
Published 1995-03-01 · retrieved 2026-09-08T21:46:11Z - 85Published evidence snapshotSomatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.Open ↗
pubmed · T3
Published 1994-01-01 · retrieved 2026-09-09T18:03:34Z - 86Published evidence snapshotSandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships.Open ↗
pubmed · T3
Published 1996-08-01 · retrieved 2026-09-08T21:46:09Z